Ziarco, a Canterbury, UK-based biopharmaceutical company focused on inflammatory skin diseases, closed $33.1m in Series B funding.
The round was led by New Enterprise Associates and Lundbeckfond Ventures with participation from new investor Amgen Ventures and existing investors BVF Partners L.P. and Pfizer Venture Investments. In conjunction with the funding, Ed Mathers, a partner at NEA, has been appointed chairman of Ziarco’s board of directors while Johan Kördel, a senior partner at Lundbeckfond Ventures, joined the board.
Led by Mike Yeadon, Ph.D., President and Chief Executive Officer, Ziarco is advancing:
– ZPL-389, a selective histamine H4 receptor antagonist suitable for oral administration, and
– ZPL-521, a topical cytosolic phospholipase A2 (cPLA2) inhibitor.
The company plans to use the proceeds to generate clinical Proof-of-Concept data in patients for ZPL-389 and ZPL-521, in atopic dermatitis and psoriasis, respectively.